{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:06:58Z","timestamp":1790165218703,"version":"4.1.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Clonal hematopoiesis of indeterminate potential (CHIP), the age-related expansion of hematopoietic stem cells carrying leukemia-associated somatic mutations, is common in patients with cancer and is increasingly detected during tumor-only genomic profiling and cell-free DNA sequencing. In this narrative review, we assess epidemiological, mechanistic, and clinical evidence at the interface between CHIP and cancer immunotherapy using a three-level hierarchy: established inflammatory biology, suspected effects on antitumor immunity, and unresolved direct human causality. We also map the evidence by driver gene, clone size, tumor type, treatment modality, and detection context. Immunotherapy-specific data are concentrated in TET2-mutant CHIP; associations for DNMT3A and ASXL1 are weaker, and direct JAK2 data are absent. Clinical ICI cohorts report favorable TET2-associated efficacy signals and no evidence that checkpoint blockade selects CH clones. Separate studies associate CHIP with ICI myocarditis and with severe cytokine release syndrome, prolonged hematologic toxicity, and TP53-mutant clonal expansion after CAR T-cell therapy. These findings remain observational and context dependent. Current evidence does not support CHIP-guided treatment selection. Prospective, standardized studies are needed to determine whether specific CHIP phenotypes predict efficacy, toxicity, or neither.<\/jats:p>","DOI":"10.3389\/fonc.2026.1966718","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:51:52Z","timestamp":1790164312000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clonal hematopoiesis of indeterminate potential and cancer immunotherapy: a host-intrinsic immune-inflammatory modifier of treatment efficacy and toxicity"],"prefix":"10.3389","volume":"16","author":[{"given":"Longjun","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]},{"name":"Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Sheng","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College of Zhejiang Chinese Medical University","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyang","family":"Chi","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College of Zhejiang Chinese Medical University","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]},{"name":"Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2413","article-title":"Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis","volume":"44","author":"Busque","year":"2012","journal-title":"Nat Genet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12484","article-title":"Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults","volume":"7","author":"Young","year":"2016","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-769869","article-title":"Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly","volume":"130","author":"Zink","year":"2017","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2819-2","article-title":"Inherited causes of clonal haematopoiesis in 97,691 whole genomes","volume":"586","author":"Bick","year":"2020","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05448-9","article-title":"Common and rare variant associations with clonal haematopoiesis phenotypes","volume":"612","author":"Kessler","year":"2022","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0059-4","article-title":"Inflammaging: a new immune-metabolic viewpoint for age-related diseases","volume":"14","author":"Franceschi","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-019-0247-5","article-title":"Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease","volume":"17","author":"Jaiswal","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nature15252","article-title":"Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6","volume":"525","author":"Zhang","year":"2015","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2297","article-title":"Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors","volume":"4","author":"Ptashkin","year":"2018","journal-title":"JAMA Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0652-7","article-title":"High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants","volume":"25","author":"Razavi","year":"2019","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ccell.2025.09.011","article-title":"TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors","volume":"44","author":"Herbrich","year":"2026","journal-title":"Cancer Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-3329","article-title":"Response to immune checkpoint blockade is enhanced in the presence of hematopoietic TET2 inactivation","volume":"86","author":"Rondeau","year":"2026","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s40959-024-00289-z","article-title":"Clonal hematopoiesis of indeterminate potential is associated with increased risk of immune checkpoint inhibitor myocarditis in a prospective study of a cardio-oncology cohort","volume":"10","author":"Jaber Chehayeb","year":"2024","journal-title":"Cardio-Oncology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.06.008","article-title":"Clonal hematopoiesis is associated with severe cytokine release syndrome in patients treated with chimeric antigen receptor T-cell (CART) therapy","volume":"30","author":"Goldsmith","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-1587","article-title":"Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy","volume":"31","author":"Avigan","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013228","article-title":"Clonal hematopoiesis of indeterminate potential as a prognostic factor: a systematic review and meta-analysis","volume":"8","author":"Singh","year":"2024","journal-title":"Blood Adv"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.222","article-title":"Comprehensive next-generation profiling of clonal hematopoiesis in cancer patients using paired tumor-blood sequencing for guiding personalized therapies","volume":"10","author":"Li","year":"2020","journal-title":"Clin Transl Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1158\/2767-9764.CRC-24-0522","article-title":"Clonal hematopoiesis of indeterminate potential and its association with treatment outcomes and adverse events in patients with solid tumors","volume":"5","author":"Krishnan","year":"2025","journal-title":"Cancer Res Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70398","article-title":"A real-world data analysis of the impact of clonal hematopoiesis of indeterminate potential on therapeutic efficacy and adverse events of immune checkpoint inhibitors","volume":"132","author":"Fujita","year":"2026","journal-title":"Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00186","article-title":"Fitness landscape of clonal hematopoiesis under selective pressure of immune checkpoint blockade","volume":"4","author":"Miller","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.118.313225","article-title":"CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease","volume":"123","author":"Sano","year":"2018","journal-title":"Circ Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044362","article-title":"Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis","volume":"141","author":"Bick","year":"2020","journal-title":"Circulation"},{"key":"B33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4049\/jimmunol.1700559","article-title":"The loss of TET2 promotes CD8+ T cell memory differentiation","volume":"200","author":"Carty","year":"2018","journal-title":"J Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.287424","article-title":"What's hidden in plain sight? Impact of clonal hematopoiesis on the risk and progression of non-hematologic cancers","volume":"111","author":"Mart\u00ednez","year":"2026","journal-title":"Haematologica"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018825","article-title":"A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic data sets","volume":"141","author":"Vlasschaert","year":"2023","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-01014-0","article-title":"Clonal hematopoiesis in myeloid malignancies and solid tumors","volume":"6","author":"Cai","year":"2025","journal-title":"Nat Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1053\/j.seminhematol.2024.01.006","article-title":"The crossroads of cancer therapies and clonal hematopoiesis","volume":"61","author":"Singh","year":"2024","journal-title":"Semin Hematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-026-02170-6","article-title":"Clonal hematopoiesis mutation is associated with risk of incident lung cancer and death","author":"Zhu","year":"2026","journal-title":"GeroScience"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.72151","article-title":"Clonal hematopoiesis in colorectal cancer: mechanisms and implications","volume":"15","author":"Xia","year":"2026","journal-title":"Cancer Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40779-025-00654-8","article-title":"Clonal hematopoiesis of indeterminate potential: a multisystem hub bridging hematopoietic dysfunction with non-hematopoietic diseases","volume":"12","author":"Zhang","year":"2025","journal-title":"Mil Med Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abl6579","article-title":"Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential","volume":"8","author":"Nakao","year":"2022","journal-title":"Sci Adv"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1210528","article-title":"Cigarette smoke stimulates clonal expansion of Jak2V617F and TET2-\/- cells","volume":"13","author":"Ramanathan","year":"2023","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1966718\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:51:53Z","timestamp":1790164313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1966718\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":44,"alternative-id":["10.3389\/fonc.2026.1966718"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1966718","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"1966718"}}